Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Clinicaltrials.gov NCT00356460.
问 AI
Like
Bookmark
Share
View Full Paper
问 AI
Like
Bookmark
Share
View Full Paper
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma | Synapse